Biosense Webster – Health Economics & Outcomes Research 

AF Burden of Disease and Treatment

As a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, Biosense Webster, Inc. is committed to patient advocacy and raising awareness of atrial fibrillation and its available treatment options.

Atrial Fibrillation is a chronic and typically progressive disease, which burdens patients with frequent and repeated episodes over their lifetime.2

AF increases a patient’s risk of life-threatening complications, such as stroke, heart attack, and heart failure.2 Patients with AF have a 46% higher risk of mortality than individuals without AF.2,3

Biosense Webster – Health Economics & Outcomes Research

Atrial Fibrillation Burden of Disease Report

The AF Burden of Disease Report outlines the growing burden of AF on patients, caregivers and healthcare systems across Europe, emphasizing the scale and impact of the disease.

Atrial Fibrillation Burden of Disease Report

Atrial Fibrillation Management Report

The Atrial Fibrillation Management Report details 2020 guideline-recommended treatment options for AF as well as their long-term impact on clinical, patient and economic outcomes, aiming to support healthcare professionals (HCPs) when making treatment decisions.

Atrial Fibrillation Management Report


1. Zoni‐Berisso M, Lercari F, Carazza T, Domenicucci S (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 6 213‐220

2. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG et al. (2016) Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta‐ analysis. Bmj 354 i4482.

3. Boriani G, Proietti M (2017) Atrial fibrillation prevention: an appraisal of current evidence. Heart